Get the latest tech news
Proscia’s $46M Series C propels AI-driven pathology into the mainstream
Proscia raises $9M in Series C extension and secures FDA clearance to accelerate the adoption of AI-powered digital pathology for life sciences and diagnostic laboratories.
With the FDA clearance, Proscia can now bring its digital pathology solutions to diagnostic labs, addressing the mounting challenges of a global pathologist shortage and rising cancer rates. With its latest funding and FDA clearance, Proscia is poised to make that impact a reality, ushering in a new era of data-driven, AI-powered pathology that can ultimately improve patient outcomes. As the convergence of digital pathology and AI accelerates, Proscia’s open platform approach and enterprise-scale solutions make it a company to watch in the rapidly evolving healthcare technology landscape.
Or read this on Venture Beat
